tegafur / gimeracil / oteracil
Teysuno is a cancer medicine that is used to treat advanced gastric (stomach) cancer. It is used together with cisplatin (another cancer medicine).
Teysuno contains the active substances tegafur, gimeracil and oteracil.
Teysuno : EPAR - Medicine overview (PDF/150.31 KB)
First published: 30/03/2011
Last updated: 30/07/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Nordic Group B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
03/07/2020 Teysuno - EMEA/H/C/001242 - A31/0040
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Teysuno is indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.